Cliff Asness’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $643M | Sell |
3,818,037
-1,120,930
| -23% | -$166M | 0.22% | 88 |
|
|
2026
Q1 | $651M | Buy |
4,938,967
+1,667,261
| +51% | +$221M | 0.3% | 56 |
|
|
2025
Q4 | $463M | Buy |
3,271,706
+498,058
| +18% | +$72.2M | 0.24% | 90 |
|
|
2025
Q3 | $388M | Buy |
2,773,648
+1,263,633
| +84% | +$171M | 0.25% | 76 |
|
|
2025
Q2 | $190M | Buy |
1,510,015
+435,385
| +41% | +$49.9M | 0.16% | 169 |
|
|
2025
Q1 | $119M | Sell |
1,074,630
-822,261
| -43% | -$104M | 0.12% | 221 |
|
|
2024
Q4 | $259M | Buy |
1,896,891
+53,610
| +3% | +$6.63M | 0.33% | 46 |
|
|
2024
Q3 | $212M | Buy |
1,843,281
+620,226
| +51% | +$85M | 0.29% | 62 |
|
|
2024
Q2 | $167M | Buy |
1,223,055
+228,444
| +23% | +$31.3M | 0.26% | 84 |
|
|
2024
Q1 | $137M | Buy |
994,611
+255,759
| +35% | +$34.9M | 0.23% | 101 |
|
|
2023
Q4 | $97.2M | Buy |
738,852
+364,890
| +98% | +$42M | 0.18% | 123 |
|
|
2023
Q3 | $42.1M | Buy |
373,962
+16,264
| +5% | +$1.71M | 0.09% | 277 |
|
|
2023
Q2 | $33.7M | Buy |
357,698
+126,624
| +55% | +$12.4M | 0.07% | 319 |
|
|
2023
Q1 | $22.8M | Buy |
231,074
+124,539
| +117% | +$13M | 0.05% | 430 |
|
|
2022
Q4 | $12.7M | Sell |
106,535
-7,068
| -6% | -$828K | 0.03% | 589 |
|
|
2022
Q3 | $11.9M | Buy |
113,603
+81,596
| +255% | +$8.28M | 0.03% | 592 |
|
|
2022
Q2 | $3.1M | Sell |
32,007
-40,742
| -56% | -$3.76M | 0.01% | 945 |
|
|
2022
Q1 | $6.79M | Sell |
72,749
-27,772
| -28% | -$2.35M | 0.01% | 781 |
|
|
2021
Q4 | $8.56M | Buy |
100,521
+52,958
| +111% | +$4.87M | 0.02% | 720 |
|
|
2021
Q3 | $4.54M | Buy |
47,563
+7,052
| +17% | +$666K | 0.01% | 835 |
|
|
2021
Q2 | $3.91M | Sell |
40,511
-1,580
| -4% | -$151K | 0.01% | 916 |
|
|
2021
Q1 | $4.09M | Buy |
42,091
+30,775
| +272% | +$3.23M | 0.01% | 876 |
|
|
2020
Q4 | $1.06M | Sell |
11,316
-37,808
| -77% | -$3.65M | ﹤0.01% | 1474 |
|
|
2020
Q3 | $4.72M | Buy |
49,124
+957
| +2% | +$111K | 0.01% | 787 |
|
|
2020
Q2 | $5.88M | Buy |
48,167
+14,097
| +41% | +$1.56M | 0.01% | 745 |
|
|
2020
Q1 | $2.95M | Buy |
34,070
+9,302
| +38% | +$910K | 0.01% | 947 |
|
|
2019
Q4 | $2.65M | Buy |
24,768
+13,257
| +115% | +$1.39M | ﹤0.01% | 1160 |
|
|
2019
Q3 | $1.03M | Buy |
11,511
+1,192
| +12% | +$111K | ﹤0.01% | 1514 |
|
|
2019
Q2 | $850K | Sell |
10,319
-51,329
| -83% | -$4.21M | ﹤0.01% | 1554 |
|
|
2019
Q1 | $5.43M | Sell |
61,648
-57,876
| -48% | -$4.84M | 0.01% | 954 |
|
|
2018
Q4 | $8.54M | Buy |
119,524
+53,487
| +81% | +$5.12M | 0.01% | 778 |
|
|
2018
Q3 | $8.12M | Buy |
66,037
+38,582
| +141% | +$4.38M | 0.01% | 849 |
|
|
2018
Q2 | $2.7M | Buy |
27,455
+11,732
| +75% | +$1.05M | ﹤0.01% | 1287 |
|
|
2018
Q1 | $1.3M | Buy |
+15,723
| New | +$1.33M | ﹤0.01% | 1559 |
|
|
2017
Q2 | – | Sell |
-78,622
| Closed | -$3.4M | – | 2218 |
|
|
2017
Q1 | $3.4M | Sell |
78,622
-69,075
| -47% | -$2.96M | ﹤0.01% | 1169 |
|
|
2016
Q4 | $5.72M | Sell |
147,697
-57,577
| -28% | -$2.61M | 0.01% | 983 |
|
|
2016
Q3 | $10.4M | Buy |
205,274
+180,167
| +718% | +$8.97M | 0.02% | 753 |
|
|
2016
Q2 | $1.14M | Sell |
25,107
-4,069
| -14% | -$187K | ﹤0.01% | 1561 |
|
|
2016
Q1 | $1.15M | Sell |
29,176
-43,670
| -60% | -$1.73M | ﹤0.01% | 1519 |
|
|
2015
Q4 | $4.12M | Sell |
72,846
-61,128
| -46% | -$3.11M | 0.01% | 966 |
|
|
2015
Q3 | $5.33M | Sell |
133,974
-48,159
| -26% | -$2.33M | 0.01% | 799 |
|
|
2015
Q2 | $8.7M | Buy |
182,133
+67,733
| +59% | +$2.87M | 0.02% | 649 |
|
|
2015
Q1 | $4.54M | Buy |
114,400
+51,200
| +81% | +$1.83M | 0.01% | 808 |
|
|
2014
Q4 | $1.41M | Sell |
63,200
-8,400
| -12% | -$159K | ﹤0.01% | 1486 |
|
|
2014
Q3 | $1.12M | Sell |
71,600
-122,400
| -63% | -$1.83M | ﹤0.01% | 1552 |
|
|
2014
Q2 | $2.88M | Sell |
194,000
-260,964
| -57% | -$3.68M | 0.01% | 1125 |
|
|
2014
Q1 | $7.33M | Buy |
454,964
+90,164
| +25% | +$1.54M | 0.02% | 698 |
|
|
2013
Q4 | $3.41M | Buy |
364,800
+41,700
| +13% | +$407K | 0.01% | 1054 |
|
|
2013
Q3 | $3.66M | Buy |
323,100
+135,700
| +72% | +$1.87M | 0.01% | 960 |
|
|
2013
Q2 | $2.51M | Buy |
+187,400
| New | +$2.3M | 0.01% | 1156 |
|
Other funds holding NBIX
VPC
Cliff Asness's NBIX Position: Q2 2026 in Review
Cliff Asness reduced its Neurocrine Biosciences (NBIX) stake by 23% in Q2 2026, selling an estimated $166M and leaving 3,818,037 shares worth $643M. The position accounts for 0.22% of the portfolio, ranked #88.
Cliff Asness first reported a position in NBIX in Q2 2013 and has held it in 50 quarters since. The position peaked at $651M in Q1 2026. 771 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.
- Cliff Asness held 3,818,037 shares of Neurocrine Biosciences worth $643M as of Q2 2026.
- Cliff Asness sold 1,120,930 Neurocrine Biosciences shares in Q2 2026, an estimated $166M.
- Neurocrine Biosciences made up 0.22% of Cliff Asness's portfolio in Q2 2026, its #88 holding.
- Cliff Asness first reported a position in Neurocrine Biosciences in Q2 2013 and has held it in 50 quarters since.
- Cliff Asness's Neurocrine Biosciences position peaked at $651M in Q1 2026.
- 771 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.
Based on AQR Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.